NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
17 trialsNCT01120249 2025-09-16
S0931
SWOG Cancer Research Network
Phase 3 Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03138512 2024-12-18
CheckMate 914
Bristol-Myers Squibb
Phase 3 Completed
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT00920816 2022-05-06
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Pfizer
Phase 3 Completed
NCT00369564 2021-08-11
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
University of South Florida
Phase 3 Completed
NCT00678392 2019-01-09
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
Pfizer
Phase 3 Completed
NCT00087022 2018-11-27
ARISER
Heidelberg Pharma AG
Phase 3 Completed
NCT00540969 2018-11-21
Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT01606787 2018-10-15
Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00606632 2018-10-02
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
Heidelberg Pharma AG
Phase 3 Completed
NCT00375674 2018-09-21
S-TRAC
Pfizer
Phase 3 Completed
NCT00631371 2016-04-27
INTORACT
Pfizer
Phase 3 Completed
NCT00410124 2013-01-15
RECORD-1
Novartis
Phase 3 Completed
NCT00065468 2012-10-25
ARCC
Pfizer
Phase 3 Completed